tirzepatide / niacinamide injection + Tirzepatide Injection - Weight Loss

Add-on to metformin SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly

Laboratory investigations contribute to the broader scientific understanding of peptide structure, stability and molecular interactions

Selective DPP4 inhibitors (second generation) were not shown to compromise immune function, as evaluated using in vitro assays of T cell activation

Common solvents in Semaglutide synthesis include dimethylformamide (DMF), dichloromethane (DCM), acetonitrile, trifluoroacetic acid (TFA), and N-methylpyrrolidone (NMP)

Additive gastrointestinal effects : Tirzepatide commonly causes nausea, vomiting, diarrhea, and constipation, particularly during dose escalation